Abstract
Realization of part of clinical trial called: Randomized double-blind , controlled clinical phase III trial with parallel groups evaluating intravenous volasertib in combination with low-dose subcutaneous cytarabine compared with placebo in combination with low-dose cytarabine in patients aged over 65 years with untreated acute myeloid leukemia unsuitable for intensive treatment to induce remission